Effectiveness of triplet chemotherapy plus bevacizumab intensive regimen (FIr-B/FOx) and secondary liver surgery according to KRAS genotype in metastatic colorectal cancer (MCRC).

Gemma Bruera,Katia Cannita,D. Di Giacomo,Giancarlo Troncone,Antonio Marchetti,Gino Coletti,Jean-Christophe Sabourin,Mario Tosi,Corrado Ficorella,Enrico Ricevuto

Effectiveness of triplet chemotherapy plus bevacizumab intensive regimen (FIr-B/FOx) and secondary liver surgery according to KRAS genotype in metastatic colorectal cancer (MCRC).

2011

Gemma Bruera
Katia Cannita
D. Di Giacomo
Giancarlo Troncone
Antonio Marchetti
Gino Coletti
Jean-Christophe Sabourin
Mario Tosi
Corrado Ficorella
Enrico Ricevuto

e14028 Background: FIr-B/FOx association, consisting of triplet chemotherapy plus bevacizumab, can increase activity, efficacy and resection rate of liver metastases in MCRC patients (Bruera G et a...

Keywords:

Bevacizumab
Regimen
KRAS
Colorectal cancer
Genotype
General surgery
Medicine
Chemotherapy
Surgery
liver surgery
triplet chemotherapy
Internal medicine
Oncology
Resection

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations